Skip to Content Skip to Search
GSK investigator working in our lab

GSK at ASH 2020

GSK at the American Society of Hematology Annual Meeting 2020

GSK scientists are focused on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential. With 14 ongoing research programs, our own R&D is bolstered by the power of collaborations and smart scientific partnerships that will expand the ability of both our portfolio and pipeline to tackle the areas of greatest need in cancer.

At ASH, we are proud to share updates from 13 studies and analyses, including new data from our DRiving Excellence in Approaches to Multiple Myeloma (DREAMM) clinical trial program.

If you’re attending ASH virtually and joining the conversation online, be sure to follow us on Twitter Facebook Instagram LinkedIn for live updates.